Zurück zu den Rankings

Exponent, Inc. (EXPO)

NEUTRAL
IndustrialsEngineering & ConstructionUnited States

Fundamental

65

Kurs

$69.73

Marktkapitalisierung

$3.39B

Teil 1 · Was das Unternehmen wert ist

Übersicht

Exponent, Inc., together with its subsidiaries, operates as a science and engineering consulting company in the United States and internationally. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health. It provides services in the areas of biomechanics, biomedical engineering and sciences, civil and structural engineering, construction consulting, data sciences, electrical engineering and computer science, human factors, materials and corrosion engineering, mechanical engineering, metallurgical and corrosion engineering polymer and chemistry, thermal sciences, and vehicle engineering. The company also offers services in the areas of chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences, and health sciences. In addition, it provides proactive and reactive product safety, litigation support, and technical, regulatory services. It serves clients in chemical, construction, consumer products, energy, food, beverage and nutrition, government, life sciences, insurance, manufacturing, technology, industrial equipment, transportation, and other sectors. The company was formerly known as The Failure Group, Inc. and changed its name to Exponent, Inc. in 1998. The company was founded in 1967 and is headquartered in Menlo Park, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Bilanz & Liquidität

Umsatz

$632M

Letzte 12 Monate (bis 3.7.2026)

Nettogewinn

$112M

Letzte 12 Monate (bis 3.7.2026)

Freier Cashflow

$122M

Gesamtes Eigenkapital

$390M

Gesamtverbindlichkeiten

$387M

Current Ratio

1.98

Zinsdeckungsgrad

-

Schulden/EBITDA

0.62

Gewinn je Aktie

Umsatz & Nettogewinn

Freier Cashflow

Ertragsaufschlüsselung

Historische Aufstellung

Margen im Zeitverlauf

Verschuldung im Zeitverlauf

Wie schwer die Schulden wiegen

Wachstumsraster

Wachstum — Umsatz

Innerer-Wert-Schätzung

General caseFair bewertet

Innerer Wert

$63.65

Aktueller Kurs

$69.73

Sicherheitsmarge

-9.6%

Innerer-Wert-Spanne

$45.42 - $81.89

Bewertungsmethoden

Analyst price target:$84.00
Discounted cash flow (DCF):$62.39
Earnings multiple (P/E):$59.46
Graham growth formula:$40.11
Earnings power value (EPV):$22.15
Justified P/B:$43.75
Dividend discount (Gordon):$29.62
P/FFO, funds from operations:Not enough data to compute it
Mid-cycle earnings:$60.80
Revenue multiple:Not enough data to compute it
Analystenkonsens:Starker Kauf (8B / 2H / 0S)
Letzte Gewinnüberraschung:+6.95%

Bewertungskennzahlen

P/E-Verhältnis

31.88

ROE

27.2%

P/B-Verhältnis

11.66

P/FCF

31.00

Bruttomarge

-

ROIC

20.4%

Rentabilitäts-Radar

Value Creation (Economic Moat)

ROIC

20.4%

WACC

8.1%

ROIC − WACC

+12.3 pp

ROIC exceeds the cost of capital — the company is creating value for shareholders.

Fundamentalanalyse-Kriterien

Bestanden (18)

  • EPS shows upward trend
  • Price CAGR 8.82%
  • ROIC 20.4%
  • Debt/Equity ratio
  • Operating Margin 20.2%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • ROE 27.9%
  • Revenue Growth 5Y 7.8%
  • Analyst Consensus 80% Buy
  • Earnings Surprise avg 4.3%
  • Earnings Quality (OCF/NI) 1.06
  • Share Dilution -0.9%
  • Piotroski F-Score 5/9

Nicht bestanden (7)

  • EPS CAGR 2.16%
  • P/FCF 31.00
  • P/B Ratio 11.66
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • PEG Ratio 4.90
  • Net Margin Trend 17.7% vs 18.3%

Nicht verfügbar (3)

  • Gross Margin NaN%
  • Dividend Payout NaN%
  • Interest Coverage

Piotroski F-Score

5/9

Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit

score
criteria

Gewinnqualität

1.06

Hohe Qualität: Gewinne durch Cashflow gedeckt

Aktienverwässerung

-0.9%

Aktienrückkäufe. Aktionärsfreundlich

Unternehmensführung

Führungsteam

NamePositionAlter
Dr. Catherine Ford Corrigan P.E., Ph.D.CEO & Director56
Mr. Richard L. Schlenker Jr.Executive VP, Corporate Secretary & Director59
Dr. Maureen T. F. Reitman F.S.P.E., P.E., Sc.D.Group Vice President56
Dr. Joseph Rakow Ph.D.Group Vice President48
Dr. Joseph Sala Ph.D.Group Vice President48
Dr. John D. Pye P.E., Ph.D.President54
Dr. Bernard Ross P.E., Ph.D.Co-Founder & Principal Engineer-
Mr. Eric R. AndersonChief Financial Officer50
Ms. Gina FlynnVP of Legal & General Counsel-
Mr. Brian KundertChief Human Resources Officer50

Prüfungsrisiko

9

Vorstandsrisiko

2

Vergütungsrisiko

4

Aktionärsrechterisiko

2

Teil 2 · Der Preis und der Einstiegszeitpunkt

Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.

Latest News

Recent headlines for EXPO, sourced from Markets Gazette.

No recent news for EXPO.